Onchocerciasis Control: Vision for the Future from a Ghanian perspective

Mark J Taylor, Kwablah Awadzi, María-Gloria Basáñez, Nana Biritwum, Daniel Boakye, Boakye Boatin, Moses Bockarie, Thomas S Churcher, Alex Debrah, Geoffrey Edwards, Achim Hoerauf, Sabine Mand, Graham Matthews, Mike Osei-Atweneboana, Roger K Prichard, Samuel Wanji, Ohene Adjei, Mark J Taylor, Kwablah Awadzi, María-Gloria Basáñez, Nana Biritwum, Daniel Boakye, Boakye Boatin, Moses Bockarie, Thomas S Churcher, Alex Debrah, Geoffrey Edwards, Achim Hoerauf, Sabine Mand, Graham Matthews, Mike Osei-Atweneboana, Roger K Prichard, Samuel Wanji, Ohene Adjei

Abstract

Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan(R), Merck & Co., Inc.) through the Mectizan Donation Programme. Recently, concern has been raised over the appearance of suboptimal responses to ivermectin in Ghana - highlighting the potential threat of the development of resistance to ivermectin. This report summarises a meeting held in Ghana to set the research agenda for future onchocerciasis control. The aim of this workshop was to define the research priorities for alternative drug and treatment regimes and control strategies to treat populations with existing evidence of suboptimal responsiveness and define research priorities for future control strategies in the event of the development of widespread ivermectin resistance.

References

    1. Boatin BA, Richards FO., Jr Control of onchocerciasis. Adv Parasitol. 2006;61:349–394. doi: 10.1016/S0065-308X(05)61009-3.
    1. Thylefors B, Lawrence J, (Eds) Twenty Years of Mectizan Mass Treatment: Past, Present and Future Perspectives. 2008. pp. S3–S45.
    1. Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas. Filaria J. 2004;2:S2.
    1. Hodgkin C, Molyneux DH, Abiose A, Philippon B, Reich MR, Remme JH, Thylefors B, Traore M, Grepin K. The future of onchocerciasis control in Africa. PLoS Negl Trop Dis. 2007;1:e74. doi: 10.1371/journal.pntd.0000074.
    1. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2003;2:2. doi: 10.1186/1475-2883-2-2.
    1. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga N, Duke BO. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360:203–210. doi: 10.1016/S0140-6736(02)09456-4.
    1. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, De Vlas SJ, Bonneux L, Habbema JD. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:204–210.
    1. Klager S, Whitworth JA, Post RJ, Chavasse DC, Downham MD. How long do the effects of ivermectin on adult Onchocerca volvulus persist? Trop Med Parasitol. 1993;44:305–310.
    1. Chavasse DC, Post RJ, Lemoh PA, Whitworth JA. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop Med Parasitol. 1992;43:256–262.
    1. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, Lazdins-Helds JK, Ardrey AE, Addy ET, Quartey BT, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98:231–249. doi: 10.1179/000349804225003253.
    1. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, Ahmed K, Boatin BA, Boakye DA, Edwards G. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98:359–370. doi: 10.1179/000349804225003442.
    1. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369:2021–2029. doi: 10.1016/S0140-6736(07)60942-8.
    1. Ali MM, Mukhtar MM, Baraka OZ, Homeida MM, Kheir MM, Mackenzie CD. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop. 2002;84:49–53. doi: 10.1016/S0001-706X(02)00117-1.
    1. Prichard RK, Hall CA, Kelly JD, Martin IC, Donald AD. The problem of anthelmintic resistance in nematodes. Aust Vet J. 1980;56:239–251. doi: 10.1111/j.1751-0813.1980.tb15983.x.
    1. Basáñez MG, Pion SD, Boakes E, Filipe JA, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:310–322. doi: 10.1016/S1473-3099(08)70099-9.
    1. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO, Boussinesq M, Prichard RK. Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment. PLoS Negl Trop Dis. 2007;1:e72. doi: 10.1371/journal.pntd.0000072.
    1. Prichard RK. Ivermectin resistance and overview of the Consortium for Anthelmintic Resistance SNPs. Expert Opin Drug Discov. 2007;2:S41–S52. doi: 10.1517/17460441.2.S1.S41.
    1. Johnston KL, Taylor MJ. Wolbachia in filarial parasites: targets for filarial infection and disease control. Curr Infect Dis Rep. 2007;9:55–59. doi: 10.1007/s11908-007-0023-2.
    1. Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol. 2005;60:245–284. doi: 10.1016/S0065-308X(05)60004-8.
    1. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis. 2008;21:673–681. doi: 10.1097/QCO.0b013e328315cde7.
    1. Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 2001;357:1415–1416. doi: 10.1016/S0140-6736(00)04581-5.
    1. Hoerauf A, Mand S, Volkmann L, Buttner M, Marfo-Debrekyei Y, Taylor M, Adjei O, Buttner DW. Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect. 2003;5:261–273. doi: 10.1016/S1286-4579(03)00026-1.
    1. Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fleischer B, Buttner DW. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. 2000;355:1242–1243. doi: 10.1016/S0140-6736(00)02095-X.
    1. Hoerauf A, Specht S, Buttner M, Pfarr K, Mand S, Fimmers R, Marfo-Debrekyei Y, Konadu P, Debrah AY, Bandi C, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol. 2008;197:295–311. doi: 10.1007/s00430-007-0062-1.
    1. Hoerauf A, Specht S, Marfo-Debrekyei Y, Buttner M, Debrah AY, Mand S, Batsa L, Brattig N, Konadu P, Bandi C, et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitol Res. 2008
    1. Keiser PB, Reynolds SM, Awadzi K, Ottesen EA, Taylor MJ, Nutman TB. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis. 2002;185:805–811. doi: 10.1086/339344.
    1. Saint Andre A, Blackwell NM, Hall LR, Hoerauf A, Brattig NW, Volkmann L, Taylor MJ, Ford L, Hise AG, Lass JH, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science. 2002;295:1892–1895. doi: 10.1126/science.1068732.
    1. Specht S, Mand S, Marfo-Debrekyei Y, Debrah AY, Konadu P, Adjei O, Buttner DW, Hoerauf A. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res. 2008;103:1303–1309. doi: 10.1007/s00436-008-1133-y.
    1. Townson S, Tagboto S, McGarry HF, Egerton GL, Taylor MJ. Onchocerca parasites and Wolbachia endosymbionts: evaluation of a spectrum of antibiotic types for activity against Onchocerca gutturosa in vitro. Filaria J. 2006;5:4. doi: 10.1186/1475-2883-5-4.
    1. Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G. Effects of Bay 44-4400, a new cyclodepsipeptide, on developing stages of filariae (Acanthocheilonema viteae, Brugia malayi, Litomosoides sigmodontis) in the rodent Mastomys coucha. Acta Trop. 2001;80:19–28. doi: 10.1016/S0001-706X(01)00144-9.
    1. Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int J Parasitol. 2001;31:1515–1522. doi: 10.1016/S0020-7519(01)00263-6.
    1. Amazigo U, Boatin B. The future of onchocerciasis control in Africa. Lancet. 2006;368:1946–1947. doi: 10.1016/S0140-6736(06)69786-9.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj